Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.713 USD | -5.19% | -0.62% | -4.10% |
Apr. 02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
Mar. 29 | KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.10% | 18.91M | |
+32.36% | 695B | |
+26.51% | 568B | |
-4.40% | 361B | |
+19.46% | 330B | |
+3.50% | 283B | |
+17.26% | 239B | |
+8.02% | 204B | |
-7.53% | 198B | |
+8.62% | 168B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Oppenheimer Adjusts Kala Pharmaceuticals' Price Target to $2 From $5, Maintains Outperform Rating